About F2g
F2g is a company based in Manchester (United Kingdom) founded in 1998.. F2g has raised $353.35 million across 13 funding rounds from investors including Novartis, Gov.uk and TD Securities. The company has 27 employees as of December 31, 2020. F2g offers products and services including Antifungal Drugs and Early Access Programs. F2g operates in a competitive market with competitors including Scynexis, Amplyx Pharmaceuticals, Biosergen, Elion Therapeutics and Viamet Pharmaceuticals, among others.
- Headquarter Manchester, United Kingdom
- Employees 27 as on 31 Dec, 2020
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name F2g Ltd
- Date of Incorporation 10 Jun, 1998
- Jurisdiction MANCHESTER, ENGLAND
-
Annual Revenue
-
Net Profit
$-56.81 M (USD)-43as on Dec 31, 2021
-
EBITDA
$-64.5 M (USD)-43as on Dec 31, 2021
-
Total Equity Funding
$353.35 M (USD)
in 13 rounds
-
Latest Funding Round
$100 M (USD), Series H
Sep 12, 2024
-
Investors
Novartis
& 22 more
-
Employee Count
27
as on Dec 31, 2020
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of F2g
F2g offers a comprehensive portfolio of products and services, including Antifungal Drugs and Early Access Programs. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Medications targeting rare fungal infections through innovative development.
Initiatives providing investigational therapies for patients with fungal diseases.
Unlock access to complete
Unlock access to complete
Funding Insights of F2g
F2g has successfully raised a total of $353.35M across 13 strategic funding rounds. The most recent funding activity was a Series H round of $100 million completed in September 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 13
- Last Round Series H — $100.0M
-
First Round
First Round
(10 Sep 2002)
- Investors Count 23
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep, 2024 | Amount | Series H - F2g | Valuation | AMR Action Fund , ICG | |
| Aug, 2022 | Amount | Series E - F2g | Valuation | Forbion , Sofinnova Partners | |
| Aug, 2020 | Amount | Series D - F2g | Valuation | Cowen , Novo Holdings |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in F2g
F2g has secured backing from 23 investors, including venture fund and institutional investors. Prominent investors backing the company include Novartis, Gov.uk and TD Securities. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are made in antimicrobial resistance treatment development.
|
Founded Year | Domain | Location | |
|
ICG is recognized as a global alternative asset manager.
|
Founded Year | Domain | Location | |
|
Private equity and venture capital fund focused on the healthcare sector
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by F2g
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - F2g
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
F2g Comparisons
Competitors of F2g
F2g operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Scynexis, Amplyx Pharmaceuticals, Biosergen, Elion Therapeutics and Viamet Pharmaceuticals, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developing glucan synthase inhibitors for the treatment of fungal infections.
|
|
| domain | founded_year | HQ Location |
Broad-spectrum fungal enzyme inhibitors are developed by clinical-stage biopharma.
|
|
| domain | founded_year | HQ Location |
Anti-fungal therapeutics are developed against invasive fungal diseases.
|
|
| domain | founded_year | HQ Location |
Therapeutics for invasive fungal infections are developed by Elion Therapeutics.
|
|
| domain | founded_year | HQ Location |
Therapies for chronic fungal infections are developed using metalloenzyme inhibitors.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on F2g
Frequently Asked Questions about F2g
When was F2g founded?
F2g was founded in 1998 and raised its 1st funding round 4 years after it was founded.
Where is F2g located?
F2g is headquartered in Manchester, United Kingdom. It is registered at Manchester, Greater Manchester, United Kingdom.
Who is the current CEO of F2g?
Francesco Maria Lavino is the current CEO of F2g.
Is F2g a funded company?
F2g is a funded company, having raised a total of $353.35M across 13 funding rounds to date. The company's 1st funding round was a Series D of $60.8M, raised on Sep 10, 2002.
How many employees does F2g have?
As of Dec 31, 2020, the latest employee count at F2g is 27.
What does F2g do?
F2G was founded in 1998 in Manchester, United Kingdom, within the biotechnology sector. Antifungal drugs are discovered and developed to address systemic infections in immune-compromised patients, where mortality rates are elevated. Proprietary genomics technology and screening processes are employed to identify novel chemical series exhibiting potent activity. The F3 series of anti-mold compounds is advanced, including the lead candidate F901318 from the Orotomide class, which targets dihydroorotate dehydrogenase (DHODH).
Who are the top competitors of F2g?
F2g's top competitors include Scynexis, Amplyx Pharmaceuticals and Biosergen.
What products or services does F2g offer?
F2g offers Antifungal Drugs and Early Access Programs.
Who are F2g's investors?
F2g has 23 investors. Key investors include Novartis, Gov.uk, TD Securities, European Investment Bank, and ICG.